NASDAQ:SVNT
$12.72
(2/9 12:56PM)
+2.2%
| Open | $12.65 |
Mkt Cap | $829.5 Million |
| High | $12.85 |
52Wk High | $16.62 |
| Low | $12.46 |
52Wk Low | $3.45 |
| Volume | 223,440 |
Avg Vol 10D | 1.1 Million |
Ockham's Rating/Recommendation Summary
Rating specific information requires Premium Access.
Buy Now
or
Learn More about Ockham's Features and Services.
SVNT Revenue
As a value investing shop, we are interested in seeing how SVNT's revenues measure up against past performances. One easily understandable way of doing that is to compare Price to Sales per share levels over a given time frame. Assuming it is available, Ockham prefers to look at ten years of history (for this stock there are 10 years of history available) and we weigh recent years more heavily. This allows us to find weighted average historical high and low Price to Sales ratios, which give us a better idea of the stock's current underlying value. Using this method, we have established a high range for Price to Sales of 116.98x and the low end of the range at 18.05x.
With respect to these historically rational metrics, notice that the current Price to Sales per share ratio for SVNT of 248.80x is significantly above its historical average. This places SVNT at the upper end of its historical range relative to sales per share and makes it difficult to suggest an attractive price outlook. At current sales per share levels, we would need to see a decline in the Price to Sales ratio of 268% merely to return SVNT to its historical average.
SVNT Cash Earnings
Price to Cash Earnings analysis is inappropriate for this company due to an insufficient positive cash earnings history. Rather than calculating a potentially misleading Price to Cash Earnings analysis, we have chosen to give SVNT a neutral Price to Cash Earnings outlook at this time. However, we should point out that this metric is a significant element in Ockham’s methodology to analyzing the outlook for any company. Therefore, for SVNT, our assessment is now more dependent on the Price to Sales analysis, and investors should be cautious with a company with very limited, if any, positive cash earnings.
SVNT Dividends
While it is not necessary to pay an attractive dividend or a dividend at all, to receive a positive rating from Ockham, we view dividends as an additionally helpful measure in determining the future potential of any company. As of the time of this report, our data provider does not have historical data for SVNT. Therefore, we are not utilizing the dividends portion in our study. So, we do not know whether SVNT currently pays a dividend at present or not, we have an "expected dividend" payment listed in key fundamentals but cannot varify it.
Savient Pharmaceuticals, Incorporated (SVNT) Discussed on Fox Business's The Opening Bell on Fox Business
Savient Pharmaceuticals, Incorporated is in the news. Find out how this impacts SVNT trading on Ockham Research.
Ford shares up 10% already in the early going here op optimism over july sales, senior execs saying that the auto maker on track to report its first monthly sales gain in two years. And number one, SAVIENT PHARMACEUTICALS saying that the food and drug administration declined to approve on its drug for chronic gout. The approval was widely expected by shareholders here.
“… inistration declined to approve on its drug for chronic gout. The approval was widely expected by shareholders here. …”
Savient Pharmaceuticals, Incorporated (SVNT) Discussed on Fox Business's The Opening Bell on Fox Business
Savient Pharmaceuticals, Incorporated is in the news. Find out how this impacts SVNT trading on Ockham Research.
Pricing a secondary common stock offering and investors not necessary lie liking the dilutive effect of the move and SAVIENT PHARMACEUTICALS hit hard and the company announcing fda is reviewing one of its gout drugs and others i'm watching,
“… Pricing a secondary common stock offering and investors not necessary lie liking the dilutive effect of the move and SAVIENT PHARMACEUTICALS hit hard and the company announcing fda is reviewing one of its gout drugs and others i'm watching, …”